All Stocks/Healthcare/WAT

WATERS CORP /DE/

WAT
HealthcareDiagnostics & Research Website
Price ChartPowered by TradingView
Ask about WATAI research agent
Alpha Score BreakdownHow it works →

Alpha Score of 47 reflects weak overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Momentum
59
Moderate
Value
22
Poor
Quality
76
Strong
Sentiment
–
no data
Key StatisticsUpdated Apr 15
P/E Ratio
42.69
Forward P/E
–
PEG Ratio
–
EPS (TTM)
7.74
Dividend Yield
–
Beta
1.23
Revenue (TTM)
–
Net Margin
20.30%
ROE
28.52%
Debt / Equity
0.55
52W High
$412.54
52W Low
$277.72
Insider ActivitySEC Form 4 filings
Buys (90d)
2
Sells (90d)
0
Net $ (90d)
+$451K
Unique insiders
2
DateInsiderRoleTypeSharesValue
Mar 16, 26Jiang WeiDirectorBUY500$145K
Mar 6, 26Fearon Richard HDirectorBUY1.0K$306K
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Marshall Wace581K$220.71MNEW
D.E. Shaw
David Shaw
352K$133.70MNEW
Citadel
Ken Griffin
173K$65.70MNEW
Point72
Steve Cohen
71K$26.84MNEW
Politicians who traded WATFrom Senate & House PTRs
PoliticianDateTypeAmount
Kevin Hern
R-OK
2026-08-13sale$1k – $15k
Debbie Dingell
D-MI
2026-02-10exchange$1k – $15k
Kevin Hern
R-OK
2026-02-09exchange$1k – $15k
Julia Letlow
R-LA
2025-12-08purchase$1k – $15k
Gilbert Cisneros
D-CA
2025-08-13purchase$1k – $15k
Lisa McClain
R-MI
2025-07-22sale$1k – $15k
Julia Letlow
R-LA
2024-10-23purchase$1k – $15k
Lois Frankel
D-FL
2019-08-29purchase$1k – $15k
About WATERS CORP /DE/

Waters Corporation is a leading provider of analytical instruments and software solutions for scientific research and quality control in laboratory environments worldwide. The company specializes in liquid chromatography, mass spectrometry, and thermal analysis technologies that deliver essential molecular and physical property information to support product development and quality assurance. Waters serves three primary markets: biopharmaceutical firms utilizing its instruments for drug development and regulatory compliance, industrial clients across various manufacturing sectors, and academic and government research institutions. The company's analytical instruments are considered gold standards in their applications, particularly in liquid chromatography-mass spectrometry for biopharmaceutical research. In early 2026, Waters is undergoing a significant merger with BD's life science and diagnostics business, which will expand its portfolio and market reach into diagnostics and discovery-related life science tools, fundamentally broadening the company's service offerings and customer concentrations.

CEO
Dr. Udit Batra Ph.D.
Employees
7,900
Quick Facts
Exchange–
SectorHealthcare
IndustryDiagnostics & Research
Market Cap–
Avg Volume872.35K
Key Dates

Earnings calendar coming soon. Subscribe to get notified when WAT reports next.

Get earnings alerts →